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TRANSPLANTATION
Inhibition of hedgehog signaling for the treatment of murine sclerodermatous
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Chronic graft-versus-host disease (cGVHD)
is a prognosis limiting complication
of allogeneic stem cell transplantation.
The molecular mechanisms underlying
cGVHD are incompletely understood, and
targeted therapies are not yet established
for clinical use. Here we examined the
role of the hedgehog pathway in sclero-
dermatous cGVHD. Hedgehog signaling
was activated in human and murine
cGVHD with increased expression of
sonic hedgehog and accumulation of the
transcription factors Gli-1 and Gli-2. Treat-
ment with LDE223, a highly selective
small-molecule antagonist of the hedge-
hog coreceptor Smoothened (Smo), abro-
gated the activation of hedgehog signal-
ing and protected against experimental
cGVHD. Preventive therapy with LDE223
almost completely impeded the develop-
ment of clinical and histologic features of
sclerodermatous cGVHD. Treatment with
LDE223 was also effective, when initiated
after the onset of clinical manifestations
of cGVHD. Hedgehog signaling stimu-
lated the release of collagen from cul-
tured fibroblasts but did not affect leuko-
cyte influx in murine cGVHD, suggesting
direct, leukocyte-independent stimula-
tory effects on fibroblasts as the patho-
mechanism of hedgehog signaling in
cGVHD. Considering the high morbidity
of cGVHD, the current lack of efficient
molecular therapies for clinical use, and
the availability of well-tolerated inhibitors
of Smo, targeting hedgehog signaling
might be a novel strategy for clinical trials
in cGVHD. (Blood. 2012;120(14):
2909-2917)
Introduction
Allogeneic bone marrow transplantation (alloBMT) represents the
standard care of a wide variety of genetic, immunologic, and
oncologic disorders.1 Immune reactions of the transplanted graft
against tumor cells contribute as graft-versus-leukemia (GVL) or
graft-versus-tumor reactions to the therapeutic effects of alloBMT.
However, the recognition of polymorphic major or minor histocom-
patibility antigens by donor T cells initiates an immune response
against host tissues, which manifests as graft-versus-host disease
(GVHD).2 GVHD is associated with a high morbidity and mortality
emerging as an important risk of alloBMT.3 GVHD can further be
subclassified into an acute form (aGVHD) and a chronic form
(cGVHD). Although several therapeutic options have improved the
outcome of aGVHD, therapeutic options for cGVHD are limited
and cGVHD still represents a major challenge after alloBMT.4-6
Approximately 40%-60% of long-term survivors after alloBMT
develop cGVHD,7 whereas frequencies up to 80% have been
reported for non HLA-identical donor-recipient constellations.8
cGVHD can manifest on virtually every organ system. However,
the skin is most commonly affected, with marked xerosis at
early-stage progressing to dermal subcutaneous fibrosis associated
with neuropathy and painful ulcers at end stage.
Three different hedgehog proteins have been identified: Sonic
hedgehog (Shh), Indian hedgehog (Ihh), and Desert hedgehog
(Dhh). Although all hedgehog proteins share significant sequence
homology, their distribution patterns differ, with Shh being the
most abundant hedgehog protein in the skin.9,10 The hedgehog
pathway is activated by binding of hedgehog proteins to the
membrane receptor Patched homolog 1 (Ptch-1). In the absence of
hedgehog proteins, Ptch-1 inhibits the co-receptor Smoothened
(Smo). Binding of hedgehog proteins induces conformational
changes of Ptch-1 that prevent the inhibitory effects on Smo. Smo
then translocates into the primary cilium and initiates a series of
intracellular events that result in the stabilization of Gli family
zinc finger transcription factors and the transcription of target
genes.11,12 The hedgehog pathway plays a critical role for cellular
differentiation during embryonic development.13-16 In the adult, the
activation of the hedgehog pathway is tightly controlled and
hedgehog signaling is inhibited by an array of different regulatory
mechanisms. This strict control is essential because uncontrolled
activation alters cellular fate and differentiation and has been
identified as a crucial step in the pathogenesis of several
malignancies.17-22 The prominent role of hedgehog signaling in
those diseases fostered the development of pharmacologic inhibi-
tors of the hedgehog pathway. Several small-molecule inhibitors of
Smo are currently evaluated for the treatment of basal cell
carcinoma and medulloblastoma. First results from those trials
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indicate that hedgehog signaling can be targeted efficiently in
humans and that this treatment is not limited by toxicity.23
We investigated in the present study the role of hedgehog
signaling in sclerodermatous cGVHD. We demonstrate that hedge-
hog signaling is activated in human and murine cGVHD and that
pharmacologic inhibition of Smo is effective for prevention and
treatment of cGVHD. Thus, Smo might be a promising molecular
target for the treatment of sclerodermatous cGVHD.
Methods
Mice
Female BALB/c (H-2d) mice were purchased from Janvier. B10.D2 (H-2d)
mice were purchased from The Jackson Laboratory. BMT was performed at
the age of 6-8 weeks under specific pathogen-free conditions. Male mice
were used as bone marrow donors and females as recipients. All mice
received sterile pellet food and water ad libitum. All animal experiments
were approved by the local ethic committee.
Mice were bred and maintained at the central animal facility of the
University of Erlangen-Nuremberg (Franz-Penzoldt-Zentrum) under spe-
cific pathogen-free conditions. This study was carried out in strict accor-
dance with international guidelines for animal care and use and in
accordance with the guidelines of the Animal Care and Use Committee of
the Government of Bavaria and the institutional guidelines of the University
of Erlangen-Nuremberg. The protocol was approved by the Government of
Bavaria (Regierung von Mittelfranken).
Human samples
Human sample collection was approved by the local ethical boards and
authorities in Erlangen, Kiel, and Manchester. Human skin samples were
obtained for diagnostics with the informed consent of the patients and
used in compliance with the regulations of the local ethics committees.
This study was conducted in accordance with the Declaration of
Helsinki. A clinical characterization of cGVHD patients is given in
Table 1. Nonfibrotic skin samples were obtained from 10 age- and
sex-matched healthy persons and 2 patients that underwent with
allogeneic BMT but did not develop cGVHD.
BMT
The B10.D23Balb/c [H-2(d)] minor histocompatibility antigen-mismatched
model, which reflects clinical and pathologic symptoms of human scleroder-
matous cGVHD, was used in this study.24,25 PBS was used to flush bone
marrow cells from bone marrow cavities of tibias and femurs followed by
erythrocyte hemolysis. No further purification or in vitro expansion of a
particular subset of cells was performed. Recipient mice [BALB/c (H-2d)]
underwent total body irradiation with 2 doses of 6 Gy separated by 3 hours.
In a modified protocol, low-dose total body irradiation was performed with
700 cGy. Sixteen hours after the second irradiation, each recipient mouse
received 2  106 splenocytes and 1  106 bone marrow cells, dissolved in
100 L PBS, from either BALB/c (H-2d) in a syngeneic or B10.D2 (H-2d)
in an allogeneic, multiple minor mismatched transplantation via tail vein
injection.24,25 The treatment was either started after stable engraftment
10 days after BMT or at the onset of first clinical signs of disease 21 days
after BMT.26 Engraftment was confirmed by quantification of leukocyte and
thrombocyte count and measurement of the Hb content.
Treatment with Smo inhibitor LDE223
LDE223, a novel and selective inhibitor of Smo, was kindly provided by
Novartis. Structurally closely related inhibitors, such as LDE225, are
currently evaluated in clinical trials in patients with basal cell carcinoma.
LDE223 was dissolved in 10% DMSO and administered in
polyethylenglycol-300 (PEG 300), as suspension, once daily in a total
volume of 100 L via oral gavage. Mice were treated with LDE223 in a
pharmacologically relevant dose of 40 mg/kg per day. Control mice
received sham treatment with the solvent PEG 300. Animals were killed
6 weeks after BMT by cervical dislocation after anesthesia with CO2.
Induction of GVL
The P815 leukemia model was used for the graft-versus-leukemia (GVL)
experiments as described.27 P815 is a mastocytoma (H2d) cell line derived
from DBA/2 mouse. Briefly, 500, 1500, or 10 000 P815 cells (Leibniz-
Institute DSMZ) were injected to each recipient along with syngeneic or
allogeneic bone marrow and splenocytes. A subgroup of allogenically
transplanted mice was treated with LDE223. Animals were monitored daily
for survival and the cause of death determined by postmortem gross
pathology examination.
Scoring of the clinical manifestations of cGVHD
Mice were monitored daily to determine the incidence and severity of
cutaneous cGVHD as well as other signs of disease, such as reduced
mobility, diarrhea, and weight loss. The following established scoring
system for cutaneous cGVHD was used: healthy appearance  0; skin
lesions with alopecia 1 cm2 in area  1; skin lesions with alopecia
1-2 cm2 in area, 2; and skin lesions with alopecia  2 cm2 in area  3.25,28
Histologic analysis
Skin samples of 1 cm2 were obtained from the upper back, fixed in
4% formalin and embedded in paraffin. Sections were stained with
hematoxylin and eosin. Dermal thickness was analyzed with a Nikon
Eclipse 80i microscope (Nikon) at 100-fold magnification by measuring the
distance between the epidermal-dermal junction and the dermal-
subcutaneous fat junction at sites of induration at 3 consecutive skin
sections of each animal.29 If not indicated otherwise, human and mouse skin
samples were treated alike.
Immunohistochemistry for Vimentin, Shh, and Gli
transcription factors
Sections of human and murine cGVHD and controls were incubated with
polyclonal rabbit anti–Gli-1 (Thermo Scientific), polyclonal rabbit anti–
Gli-2 (Abnova), polyclonal goat anti–Gli-3 (Santa Cruz Biotechnology) or
polyclonal rabbit anti–human Shh antibodies (Abcam), respectively, over-
night at 4°C. Irrelevant rabbit immunogloblulins were used as controls. The
expression of Gli-1, Gli-2, Gli-3, and Shh was visualized with secondary
antibodies labeled with horseradish peroxidase (Dako North America) and
DAB peroxidase substrate solution (Sigma-Aldrich). Counterstaining has
been performed with Vimentin (Abcam) where AlexaFluor-488 (Invitro-
gen) has been used as secondary antibody.
Table 1. Clinical characteristics of patients with
sclerodermatous cGVHD
Characteristic Value
No. of patients 8
Sex
Female, % 4 (50)
Male, % 4 (50)
Age of recipient, y, mean  SD 51.3  13.2
Age of donor, y, mean  SD 48.2  12.5
Time between HSCT and onset of cGVHD, y, mean  SD 8.7  2.1
Site biopsy
Thigh, % 6 (75)
Forearm, % 2 (25)
Therapy
CsA, % 2 (25)
MMF, % 7 (87)
HSCT indicates hematopoietic stem cell transplantation; CsA, cyclosporine A;
and MMF, mycophenolate mofetil.
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Quantification of Shh and Gli transcription factors
Shh and Gli transcription factors staining were quantified in a semiquantita-
tive manner, where 0 indicates no staining; 1, weak staining; 2, moderate
staining; and 3, strong staining of fibroblasts at 400-fold magnification at
3 randomly chosen high-power fields per patient.
Quantification of myofibroblasts
Myofibroblasts were identified by staining for -SMA using monoclonal
anti-actin -smooth muscle antibodies (Sigma-Aldrich) as described previ-
ously.30 In each section, -SMA–positive myofibroblasts were counted at
200-fold magnification at 3 randomly chosen high-power fields.
Quantification of the collagen content in lesional skin
The collagen content in the skin was analyzed with the hydroxyproline
assay as described.31 Skin punch biopsies of 3 mm in diameter obtained
from the upper back were digested in 6M HCl at 120°C for 3 hours,
chloramine T (0.06M) was added and samples were mixed and incubated at
room temperature for 20 minutes. Perchloric acid (3.15M) and
p-dimethylaminobenzaldehyde (20%) were added, and samples were
incubated at 60°C for an additional 20 minutes. The absorbance was
determined at 557 nm with a Spectra MAX 190 microplate spectrophotom-
eter (Molecular Devices).
Collagen measurements
Total soluble collagen in cell culture supernatants was quantified using the
SirCol collagen assay (Biocolor) as described previously.31 Cell culture
supernatants were incubated for 30 minutes with Sirius Red dye, an anionic
dye that binds specifically the basic side chain groups of collagens under
assay conditions. The formed Sirius Red-collagen complex was redissolved
in 0.5M NaOH. The collagen content was determined by the absorbance of
Sirius Red at 540 nm with a Spectra MAX 190 microplate spectrophotom-
eter (Molecular Devices).
FISH with murine Y chromosome paint
Tissue section were deparaffinized in xylene, rehydrated in an ethanol
series, followed by an antigen retrieval in 10mM sodium citrate for
15 minutes at 96°C. Further pretreatment of the slides and hybridization
with red labeled Y chromosome probes were performed according to
guidelines of the Mouse IDetect Chromosome Paint Probes (ID Labs).
Nuclei were visualized with 4,6-diamidino-2-phenylindole.
Quantification of infiltrating leukocytes, B cells, and
regulatory T cells
Infiltrating leukocytes were quantified in a blinded manner in skin sections
stained with hematoxylin and eosin. All images were captured with a Nikon
Eclipse 80i microscope (Nikon) at 400-fold magnification at 8 randomly
chosen high-power fields per mouse.32
Leukocyte counts in the skin were also determined by FACS for
CD45-positive cells in skin single-cell suspensions as described.33 The
number of B cells was measured as cells positive for CD45 and CD19 (both
antibodies from eBioscience) by FACS analysis.
Regulatory T cells were stained in skin sections with monoclonal
antibodies against mouse anti-FoxP3 (eBioscience) and visualized with
AlexaFluor-488–labeled secondary antibodies (Invitrogen).
Determination of BAFF levels
B-cell activating factor (BAFF) levels in murine serum were quantified by
ELISA using the Mouse BAFF/BLyS/TNFSF13B Immunoassay (R&D
Systems) according to the guidelines of the manufacturer.
Stress fiber staining
To analyze the potential of Shh to induce stress fiber development, healthy
human dermal fibroblasts were stimulated with 1 g/mL Shh for 24 hours.
After fixation with 4% paraformaldehyde, permeabilization with 0.25% Triton
X-100 and blocking with 1% BSA, stress fibers were visualized with
phalloidin as describe previously.29 Quantification of stress fibers was
performed via ImageJ (Version 1.42q, National Institutes of Health).
Quantitative real time PCR
NucleoSpin RNA II (Machery-Nagel) was used for total RNA extraction.
Reverse transcription into cDNA was performed using random hexam-
ers.34,35 Quantification of Col1a2 gene expression was done by SYBR
Green real-time PCR using the ABI Prism 7300 Sequence Detection System
(Applied Biosystems). The following primer pairs were used: human
col1a2 forward primer: 5-GGTCAGCACCACCGATGTC-3, human col1a2
reverse primer: 5-CACGCCTGCCCTTCCTTT-3. A predeveloped -actin
assay (Applied Biosystems) was used to normalize for the amounts of
loaded cDNA. Samples without enzyme in the reverse transcription
reaction served as negative controls. Unspecific signals caused by primer
dimers were excluded by no template controls and by dissociation curve
analysis. Differences were calculated with the threshold cycle (Ct) and the
comparative Ct method for relative quantification. The expression at
baseline was set to 100% for control experiments and all other results were
normalized to that and are shown as percent expression of baseline.
Statistics
Data are expressed as mean  SEM. The Wilcoxon signed rank tests for
related samples and the Mann-Whitney U test for nonrelated samples were
used for statistical analyses. P 	 .05 was considered statistically significant.
Results
Hedgehog signaling is activated in cGVHD
To analyze whether hedgehog signaling is activated in human
cGVHD, we performed immunohistochemistry for Shh in skin
sections obtained from patients with sclerodermatous cGVHD and
controls. Shh was overexpressed in skin sections of cGVHD
patients. Double staining of Shh with the fibroblast marker
vimentin demonstrated a prominent expression of Shh in dermal
fibroblasts (Figure 1A). To investigate whether the overexpression
of Shh results in activation of the hedgehog pathway, we stained for
Gli-1, Gli-2, which accumulates on activated hedgehog signaling.
The expression of Gli-1 and Gli-2 was increased in cGVHD
patients compared with controls. Gli-1 and Gli-2 accumulated in
particular in fibroblasts in section of cGVHD patients, whereas
only few vimentin-positive cells stained positive for Gli-1 or Gli-2
in nontransplanted healthy controls (Figure 1B-C). We also did not
observe an activation of hedgehog signaling in 2 patients with
allogeneic BMT and without cGVHD. Semiquantitative analyses
confirmed a significant induction of Shh, Gli-1, and Gli-2 in
sclerodermatous cGVHD compared with controls (Figure 1A-C).
Gli-3, which has been reported to counteract the stimulatory effects
of Gli-1 and Gli-2, was significantly lower than that of Gli-1 and
Gli-2 without detectable differences between cGVHD and controls
(data not shown).
Hedgehog signaling is activated in experimental cGVHD and
blocked by LDE223
We next determined whether the hedgehog signaling is also
activated in murine cGVHD. Indeed, the expression of Shh, Gil-1
and Gli-2 was increased in the skin of recipients of alloBMT
compared with syngeneic controls. Double staining of skin sections
of murine cGVHD with vimentin demonstrated a prominent
staining in fibroblasts as in human sclerodermatous cGVHD
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(Figure 2A-C). Gli-3 was hardly detectable in murine skin and was
not induced by alloBMT. Consistent with the proposed mode of
action as an inhibitor of the coreceptor Smo, LDE223 did not alter
the expression of Shh (Figure 2A). However, application of
LDE223 either in a preventive manner or as treatment initiated
after onset of clinical disease effectively inhibited hedgehog
Figure 1. Hedgehog signaling is activated in human sclerodermatous cGVHD. Shh, Gli-1, and Gli-2 were detected by immunohistochemistry in skin biopsies of cGVHD
patients and healthy volunteers. Fibroblasts were identified by staining with vimentin (n  8 each). Representative examples of cGVHD patients and controls are shown at
1000-fold magnification. (A) Shh expression was strongly increased in cGVHD patients (Scl GVHD) compared with controls. (B-C) Gli-1 and Gli-2, both downstream
transcription factor of the hedgehog pathway, accumulated in cGVHD patients with increased staining for Gli-1 (B) and Gli-2 (C), respectively, compared with controls.
Figure 2. Increased Hedgehog signaling in murine sclerodermatous cGVHD. Shh, Gli-1, and Gli-2 were detected by immunohistochemistry in skin biopsies of syngeneic
controls (synBMT), sham-treated mice receiving alloBMT (alloBMT), and recipients treated with LDE223, either in preventive or therapeutic regimens (n  6 each). Fibroblasts
were identified by double staining for vimentin. Representative images of the treatment groups and the control groups are shown at 1000-fold magnification. (A) Shh expression
was strongly increased 42 days after alloBMT compared with syngeneic controls. Consistent with the proposed mechanism of action, LDE223 did not affect the expression of
Shh in mice receiving alloBMT. (B-C) Gli-1 and Gli-2 signaling was activated in skin of mice receiving alloBMT with increased staining for Gli-1 (B) and Gli-2 (C) compared with
syngeneic controls. Preventive treatment as well as treatment of clinically manifest sclerodermatous cGVHD with LDE223 diminished the expression of both Gli-1 and Gli-2.
synBMT indicates syngeneic controls; and alloBMT, mice receiving alloBMT.
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signaling and reduced the accumulation of Gli-1 and Gli-2 in
fibroblasts on alloBMT (Figure 2B-C).
LDE223 prevents experimental GVHD
Sclerodermatous GVHD occurred in all Balb/c recipients receiving
B10.D2 bone marrow, whereas syngeneic controls showed no signs
of cGVHD. Clinical signs of systemic cGVHD in mice receiving
alloBMT included reduced mobility, diarrhea, and weight loss.
Weight loss was observed in all mice after BMT. The minimum
body weight was measured 7 days after BMT with a weight loss of
14%  1% of the total body weight in syngeneic controls and of
20%  4% in mice receiving alloBMT. The differences in body
weight between syngeneic controls and sham-treated mice receiv-
ing alloBMT increased further from 6%  4% at day 7 to
12%  4% at day 21 and 20%  3% at day 42 (Figure 3A).
Alopecia and skin ulcers as clinical signs of cGVHD became
evident 18 days after allogeneic BMT. The common clinical
composite score for cutaneous cGVHD progressively increased
from 1.27 at day 21 to 2.6 at day 42 (Figure 3B). In contrast,
syngeneic control mice did not show alopecia or skin ulcers
(Figure 3B). Histologically, a scleroderma-like picture with dermal
fibrosis, infiltration of leukocytes, and atrophy of the subcutis
was observed in recipients of alloBMT. The dermal thickness and
the hydroxyproline content increased by 1.6  0.1–fold and
2.5  0.1–fold, respectively, after 42 days compared with control
mice (P  .003 and P  .004, respectively; Figure 3C-D). The
numbers of myofibroblasts, which represent activated fibroblasts
and are considered as key players in the pathogenesis of fibrotic
disease, were 2.4  0.1–fold higher in mice receiving alloBMT
(P 	 .0001; Figure 3E). No differences in clinical or histologic
signs of sclerodermatous cGVHD were observed between mice
with low- and high-dose total body irradiation.
Treatment with LDE223 effectively prevented the clinical
manifestations of cGVHD. LDE223 reduced weight loss observed
in mice with cGVHD. The body weight of LDE223-treated mice
did not differ from that of syngeneic controls until day 23.
Thereafter, a modest difference in body weight was observed.
However, the body weight of LDE223-treated mice remained
significantly higher compared with sham-treated recipients of
alloBMT. The relative decrease in body weight was ameliorated by
65%  3% in LDE223-treated mice compared with sham-treated
mice at day 42 (Figure 3A). Treatment with LDE223 also delayed
the onset and reduced the severity of cutaneous cGVHD. In
contrast to sham-treated mice, in which first signs of cGVHD were
observed 18 days after allogeneic BMT, no clinical signs of
cutaneous cGVHD were observed in LDE223-treated mice until
day 30. At the end of the follow-up period (42 days after BMT),
a mild clinical cGVHD with a maximal composite score of
0.2 occurred in LDE223-treated mice compared with a score of
2.6 in the sham-treated mice (Figure 3B). Of note, the formation
of cutaneous ulcers was completely prevented by LDE223.
Inhibition of hedgehog signaling also ameliorated the histologic
changes of experimental cGVHD and reduced dermal fibrosis and
atrophy of the subcutis. Preventive treatment with LDE223 after
allogeneic BMT abrogated dermal thickening and maintained the
dermal thickness at the levels of syngeneic controls (P  .001 vs
sham-treated mice; Figure 3C). The hydroxyproline content was
also significantly reduced by 56%  9% (P  .004; Figure 3D).
Moreover, the differentiation of resting fibroblasts into myofibro-
blasts in mice receiving alloBMT was completely prevented by
LDE223 (P  .001; Figure 3E).
LDE223 is effective for the treatment of clinically manifest
experimental cGVHD
After demonstrating that LDE223 can prevent clinical and histo-
logic manifestations of experimental cGVHD, we next evaluated
LDE223 for the treatment of established cGVHD. In these experi-
ments, treatment with LDE223 was initiated at day 21 after the
onset of first clinical manifestations of experimental cGVHD. Mice
treated with LDE223 gained significantly more weight than
sham-treated controls (Figure 4A). The body weight increased by
27%  4% after initiation of LDE223 at day 21 until the end of the
observation period at day 42 compared with an increase of
13%  3% during the same observation period in sham-treated
mice (Figure 4A).
Figure 3. Inhibition of hedgehog signaling by LDE223
is well tolerated and prevents the clinical features of
sclerodermatous cGVHD. (A) Preventive treatment with
LDE223 impeded weight loss after alloBMT and resulted
in a significantly higher body weight. (B) The clinical
composite score for cutaneous cGVHD was significantly
lower in mice treated with LDE223 in a preventive manner
compared with sham-treated mice. (C) LDE223 pre-
vented the histologic changes of experimental scleroder-
matous cGVHD. Preventive regimen of LDE223 reduced
dermal thickening, decreased the hydroxyproline content
of the skin (D) and diminished the differentiation of resting
fibroblasts into myofibroblasts (E) compared with sham-
treated mice. Histologic analyses were performed at day
42 after transplantation. Six mice per group were ana-
lyzed. synBMT indicates syngeneic controls; and alloBMT,
mice receiving alloBMT.
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LDE 223 treatment after onset of clinical disease of cGVHD
completely inhibited progression of cutaneous cGVHD. The clini-
cal composite score in LDE223 remained at 1.1  2 after 42 days
in LDE223-treated mice, whereas it further increased to 2.5  2 in
sham-treated mice (Figure 4B). In contrast to sham-treated mice,
no cutaneous ulcers were observed in mice treated with LDE223
after the onset of cGVHD.
Consistent with the stabilization of clinical disease, inhibition
of hedgehog signaling in clinically manifest cGVHD abrogated
histologic progression. In mice receiving alloBMT, dermal thicken-
ing at day 42 was significantly reduced by 65% on treatment with
LDE223 compared with sham-treated mice (P  .003; Figure 4C).
The hydroxyproline content and the myofibroblast counts were also
significantly lower in LDE223-treated compared with sham-treated
recipients (54% for the hydroxyproline content, P  .04) and
86% for the numbers of myofibroblasts (P  .001; Figure 4D-E).
Furthermore, the dermal thickness and the numbers of myofibro-
blasts did not differ between alloBMT mice treated therapeutically
with LDE223 and recipients killed before initiation of LDE223
treatment at day 21. This suggests that inhibition of hedgehog
signaling completely inhibited histological progression of experi-
mental cGVHD.
LDE223 treatment does not reduce leukocyte infiltration
Inflammatory infiltrates are characteristic features of human and
murine sclerodermatous cGVHD. The infiltrating leukocytes, in
particular T cells, stimulate the synthesis of collagen in resident
fibroblasts by the release of profibrotic cytokines. To analyze
whether the therapeutic effects of LDE223 result from inhibition of
leukocyte influx, we quantified the number of leukocytes. Only a
minor, nonsignificant reduction in the number of leukocytes was
observed between mice receiving alloBMT treated with LDE223
and sham-treated mice (395%  4% vs 456%  10% increase
compared with syngeneic controls) by histologic analyses. FISH
analyses further confirmed that LDE223 did not affect the number
of infiltrating donor leukocytes. Consistently, no differences were
observed by FACS analyses for CD45-positive cells, suggesting
that the hedgehog pathway does not regulate leukocyte infiltration
in cGVHD. Further analyses also demonstrated no changes in
B cell and Treg counts as well as in the levels of BAFF (data
not shown).
Hedgehog signaling directly activates fibroblasts
Based on the prominent activation of hedgehog signaling in
fibroblasts in cGVHD and the comparable degree of inflammatory
cell infiltration in LDE223- and sham-treated mice, we assumed
that hedgehog signaling may directly stimulate the release of
collagen in fibroblasts. To address this hypothesis, cultured fibro-
blasts were stimulated with recombinant Shh. Shh induced the
formation of stress fibers in resting fibroblasts, which serve as
markers of fibroblast activation and differentiation into metaboli-
cally active myofibroblasts (P 	 .0001; Figure 5A). Incubation
with Shh significantly increased the mRNA levels of col 1a2 by
2.8  0.5–fold (P  .04; Figure 5B). Consistently, Shh stimulated
also the release of collagen protein into the cell culture supernatant
by 2.9  0.4–fold (P  .03; Figure 5C). Of note, the stimulatory
effects of Shh were comparable with those of TGF-, which is
considered as one of the most potent profibrotic mediators.
Effects of the pharmacologic inhibition of Smo on GVL
To investigate potential effects of targeting Smo on GVL, a P815
leukemia model with injection of different numbers of P815 cells
was analyzed. All of the syngeneic recipients that did not receive
P815 leukemia cells survived throughout the observation period,
whereas all of the syngeneic recipients that were injected with
Figure 4. Treatment with LDE223 initiated after onset of clinical disease effectively ameliorates clinical and histologic changes of sclerodermatous cGVHD.
Treatment with LDE223 on first clinical signs improved clinical features of cGVHD as evidenced by a increased recovery of the body weight after alloBMT (A) and by decreased
composite score (B). Treatment with LDE223 (C) reduced dermal thickening, (D) prevented further increase of the hydroxyproline content, and (E) reversed the differentiation
of resting fibroblasts into myofibroblasts. Six mice per group were analyzed. synBMT indicates syngeneic controls; and alloBMT, mice receiving alloBMT.
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500 P815 cells after irradiation died by day 18 (Figure 6A).
Sham-treated, allogeneically transplanted mice that received the
allogeneic bone marrow and splenocytes died by day 30. The
survival period of LDE223-treated, allogeneically transplanted
mice did not differ from that of sham-treated, allogeneically
transplanted mice. No differences in survival between LDE223-
treated and sham-treated mice were also noted on injection of
1500 P815 cells (Figure 6B). However, injection of 10 000 cells
P815 led to rapid tumor progression and death of all mice within
17 days (Figure 6C). A survival advantage because of GVL in
allogeneically transplanted mice was no longer detectable with
10 000 tumor cells. Survival did not differ between LDE223-
treated mice and sham-treated mice.
Discussion
In the present study, we demonstrate that hedgehog signaling plays
an important role in the pathogenesis of sclerodermatous cGVHD.
We observed an overexpression of Shh in human and murine
cGVHD that resulted in activation of hedgehog signaling with
accumulation of the downstream transcription factors Gli-1 and
Gli-2. Consistent with findings in other fibrotic conditions, we did
not observe changes in the expression of Gli-3 in human or murine
cGVHD. We did not find any trends between activation of
hedgehog signaling and clinical characteristics of patients with
sclerodermatous cGVHD. However, further studies with larger
patient numbers are required to finally assess potential correlations.
The overexpression of Gli-1 and Gli-2 was particularly pronounced
in fibroblasts, suggesting that fibroblasts may be the major effector
cells for the pathogenetic effects of hedgehog signaling in cGVHD.
Consistent with this hypothesis, we demonstrate that Shh potently
activates resting fibroblasts and stimulates the release of collagen
in vitro. Of note, the stimulatory effects of Shh were comparable to
that of TGF-, which is considered as the key cytokine for the
activation of fibroblasts. In contrast, inhibition of hedgehog
signaling did not reduce the number of infiltrating leukocytes.
Although we cannot exclude fine-tuning of leukocyte activation by
hedgehog signaling, these findings suggest direct stimulatory
effects on fibroblasts as the major mechanism of hedgehog
signaling in cGVHD. The stimulatory effects of Shh on fibroblasts
are likely not restricted to cGVHD but may also occur in other
diseases with aberrant activation of fibroblasts. Indeed, recent
studies in mouse models of experimental bile duct ligation and
nonalcoholic fatty liver disease implicate hedgehog signaling in
different types of liver fibrosis.36 Moreover, tumors with activated
hedgehog signaling, such as pancreatic tumors, are typically
surrounded by an excessive extracellular matrix capsule.37,38
Our study demonstrates that targeting the hedgehog pathway is
effective for the treatment of experimental cGVHD. Pharmacologic
inhibition of Smo abolished hedgehog activation in cGVHD and
ameliorated clinical and histologic features of cGVHD. Inhibition
of Smo not only reduced weight loss, alopecia, and cutaneous
Figure 5. The Hedgehog pathway regulates fibroblast activation. (A) Stimulation of human cultured fibroblasts with Shh induced stress fiber formation in resting fibroblasts
to the levels that can also be achieved by TGF- stimulation. Stress fibers were visualized with phalloidin and quantified with ImageJ Version 1.44p software. (B) Incubation
of human dermal fibroblasts with Shh increased the mRNA levels of col 1a2 as well as the release of collagen protein (C) similar to that obtained on stimulation with TGF-
(n  5 each).
Figure 6. Effects of LDE223 on GVL and survival in the P815 leukemia model.
(A-B) In mice injected with 500 (A) or 1500 (B) P815 cells, comparable survival times
were noted in LDE223-treated, allogeneically transplanted mice and sham-treated,
allogeneically transplanted mice. (C) Injection of 10 000 cells P815 led to death of all
mice within 16 days. No survival advantage of allogeneically transplanted mice was
detectable in mice injected with 10 000 tumor cells, and survival did not differ
between LDE223-treated mice and sham-treated mice. Survival over time is shown
as Kaplan-Meier curves. Nine mice per group were analyzed.
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ulcers but also prevented dermal thickening, accumulation of
collagen, and differentiation of resting fibroblasts into metaboli-
cally active myofibroblasts. Targeting Smo was effective not only
as preventive but also as a therapeutic regimen administered after
onset of clinical disease. Although further studies are essential to
better characterize the role of hedgehog signaling in scleroderma-
tous cGVHD, including additional models of cGVHD with mortal-
ity as endpoint, our findings may have direct translational implica-
tions. The prominent role of the hedgehog pathway in multiple
human cancers, such as basal cell carcinoma, pancreatic cancer,
and medulloblastoma, fostered the development of small-molecule
inhibitors against Smo, several of which are currently evaluated in
clinical trials (www.clinicaltrials.gov). In addition to Smo, other
components of hedgehog signaling, such as Shh, may also repre-
sent interesting candidates for targeted therapies. Despite the
deleterious consequences of perturbed hedgehog signaling during
embryonic development in mice, results from first clinical trials
indicate that pharmacologic targeting of the hedgehog pathway is
not limited by toxicity in adults.23,39 No dose-limiting toxicity was
reported with the oral Smo inhibitor GDC449 in a phase 1/2 trial at
doses that efficiently inhibited hedgehog signaling.23 Moreover,
only one grade 4 adverse event and no grade 5 adverse events had
occurred and only 1 of 68 treated patients withdrew because of
adverse events.23 Based on these results, GDC449 has recently
been approved by the FDA. Thus, pharmacologic inhibition of
hedgehog signaling is well tolerated, and several inhibitors of Smo
would be available for clinical trials in cGVHD. The development
of novel therapeutic approaches is warranted because of the high
morbidity and mortality of cGVHD and the current lack of efficient
molecular therapies for clinical use.2,4
In conclusion, the pathophysiology of cGVHD Hedgehog
signaling does not affect leukocyte infiltration but appears to
directly regulate fibroblast activation. Inhibition of hedgehog with
small-molecule inhibitors of Smo potently ameliorates clinical and
histologic changes of murine cGVHD in both preventive and
therapeutic regimens. Because inhibitors of Smo are available and
well tolerated, targeting hedgehog signaling might be a novel
strategy for clinical trials in cGVHD.
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